Novo Nordisk has found the formula to recover the profitability of Ozempic: fire 9,000 employees

The Pharmaceutical Novo Nordisk, manufacturer of Ozempic and Wegovy, is living one of the biggest turbulence in its history recent. After losing the favor of investors and a good part of its stock market value in the last year, the company has announced a drastic reduction of workforce that affects 9,000 employees around the world: 11.5% of the total staff. 9,000 layoffs, most in Denmark. Novo Nordisk has confirmed Through a statement the cut of 9,000 jobs in the coming years, a figure that represents 11.5% of its template globally, composed of 78,400 employees. Denmark, a country of origin of the pharmaceutical, will be the country that will receive the greatest impact of that measure, accumulating about 5,000 of the planned dismissals. The firm has not yet specified how layoffs will be distributed in the rest of international venues, since the decision is subject to “to the relevant consultations in accordance with local labor legislation.” The multinational has remarked that “this is a global transformation, and each country, headquarters or region will be affected differently,” underlining the international dimension of its labor adjustment process. Multimillionaire savings and business reorganization. With this cut, the pharmaceutical enhance business lines centered on the Research for new treatments For diabetes and obesity, putting greater emphasis on commercial initiatives. It should be remembered that, in origin, both Ozempic and Wegovy were born as a new treatment to enhance insulin generation, but its satiating effects turned out to be much more profitable. Among the objectives mentioned in the official statement include organizational simplification, the increase in speed in decision making and the reallocation of resources towards the strategic fields of the company. According to the statement, Nordisk “must evolve in a market that has become more competitive and consumer oriented”, which implies “a change of mentality and approach that allows us to be faster and faster.” According to published by Reutersthe company would have asked its employees to return to its full -time offices within that same restructuring and optimization plan for its operations. Bursatile bleeding as a trigger. The collapse of the stock market suffered by Novo Nordisk during the last year is the main trigger for the adjustment measure. As published the BBCthe price of your shares was reduced by 60% Since June 2024, losing 430,000 million in stock market capitalization. The situation was especially aggravated on July 30, with a decrease in 23% in a single day After the downward review Growth forecasts and the announcement of the relay in the executive direction. The official presentation of Mike Doustdar as the new CEO of the company has marked the beginning of this stage of changes, which aims to recover the confidence of investors and redefine the corporate culture of the company. Its first measure has had a positive impact on the markets, and after the announcement of the template cuts the value of its shares has increased by 3%. In Xataka | If you want a “miracle” medication to lose weight, you no longer resort to Ozempic: the competition is starting to overcome it Image | Flickr (News Oresund, Chemist4u)

Novo Nordisk has been made gold with Ozempic but knows that it will not last forever. So you already have two substitutes

The slimming drug market does not stop enlarging but the competition for taking the largest portion in this growing “cake” It is fierce. The American pharmaceutical Ozempic. Now the European company tries to recover its advantage. And he does it with a double ad. Roadmap. Little by little Let’s get to know more details About the drugs that Danish pharmaceuticals Novo Nordisk wants to give relief to Ozempic and Wegovy, their star treatments based on semaglutida. Different compounds, different analogues. Semaglutida is the active compound on which medications such as Ozempic and Wegovy are based. This formula, initially devised as diabetes treatment, works by serving as analogous to the GLP-1 hormone (peptide similar to type 1 glucagon), it is what is known as an agonist of hormone receptors. LPG-1 is a hormone that fulfills two functions in our body by transmitting the message that we have fed on the pancreas, activating insulin production; and to the brain, unleashing the feeling of satiety. This second function is the one that has led to the success of Ozempic and similar drugs transforming into weight loss treatments and thus achieving its present success. The new Danish pharmaceutical formulas are based on compounds that act similarly to the semaglutida, but with characteristics that make them own and, at least in principle, superior. Cagrisema Of the formulas proposed by Novo Nordis, Cagrisema is perhaps the one in a more advanced state of development. The drug is based on the semaglutida and the Cagrilintidaa compound that serves as an analogue of amiline And also of the Calcitoninacting as agonist of some of the receptors of these hormones. Amiline is a hormone similar to insulin, also segregated by the pancreas and also used for glycemic control in our body. Cagrisema therefore works as a double (or triple) analogous, however The first results They were not as positive as some expected. New data. Now we have the remaining data of the essays by the company to derter the efficacy of the drug. According to Explain Reutersthe study data showed a weight reduction of about 23% in overweight adults after 68 weeks; and 16% weight loss among people with diabetes. Those responsible for the company gave data on moderate adverse effects, which affected 79.6% of the participants; and serious, which affected 9.8% (with 6% of patients abandoning the trial). Those responsible expect the arrival of Cagrisema to the market towards the beginning of 2027. Amicretin. Last week Novo Nordisk He also announced The implementation of phase 3 tests of amicretin, one of the compounds designed to contain the legacy of the semaglutida. According to the company itself, this compound is a unimolecular agonist of prolonged action of the GLP-1 receptors and those of the amiline. One of the great novelties is that this formula is being tested not only to evaluate its subcutaneous administration but also its consumption orally. Phase 3 of clinical trials usually seeks to complete and complement the information obtained in previous trials in addition to studying additional issues such as dosage or efficiency compared to other formulas. The other novelty of Novo. In addition to the new formulas, Ozempic has also monopolized attention in the last week. He did it since the European Medicines Agency (EMA) I went on to recommend this drug as treatment for peripheral arterial disease, In Xataka | Generic medications have been trying to site Ozempic for years. And now they have found a shortcut in Canada Image | Chemist4u / News Oresund

Novo Energy wanted to stand up to Chinese batteries for electric cars. It has ended in the hands of a Chinese company

Point and apart for the soap opera of the Great European hope In the battery segment for electric cars. In the European assault on electric car industryVolvo and the Northvolt battery manufacturer founded Novo Energy. Both were Swedish and it was a Join Venture with the aim of producing batteries in Europe. It seemed that everything was going to be A ROSA pathbut a few years later and after thousands of layoffsNorthvolt sell His participation in Novo Energy A Volvo. And behind Volvo is Geelyan important Chinese holding. Culebrón. Things stopped going well for Northvolt practically from the beginning. During the first years, the European Investment Bank, BMW, Goldman Sachs or Volkswagen invested sums of hundreds of millions of euros in the company. The Swedish company, founded by two Exegutive of Tesla, became the great European promise to create batteries and be the heart of that European flying towards the electric car. In a market increasingly controlled by ChinaIt seemed like a great idea and everything pointed in good sense. In addition, together with Volvo they founded Novo Energy in 2021 to produce the batteries of both Volvo and Polestar. However, things began to twist in 2023, when it was uncovered that the company had been operating with losses of 1,000 million dollars during the first nine months of the year. And, in 2024, the situation exploded. Last nail in the coffin. Everything happened very fast. After the delays in the delivery dates, BMW canceled its agreement of 2,000 million euros, there were a series of employee deaths in work shifts, fired more than 1,600 workers in September and, shortly after, the bankruptcy arrived. In November 2024, Northvolt requested bankruptcy protectionarguing that they had 30 million in cash and, with them, they could only operate for a week. The hole they had was 5.8 billion dollars. A skinny dog, everything is fleas, and a day later one of the founders resigned, arguing that the company would need 1.2 billion dollars to save itself. After a few days of 2025 in which the company was still looking for financing, something that nobody seemed willing to do, sales arrived. It was even rumored that Catl, the main Chinese rival in battery manufacturing, I could give a hand. Volvo. After getting rid of some services, this January 29 we learned that the Swedish company sold its participation in Novo Energy to its partner in this adventure, Volvo. It is something that does not catch by surprise, since, as with BMW, Volvo saw that Northvolt’s delivery plans were not being fulfilled and in October last year he showed his interest in acquiring participation in Novo. Last week, Novo Energy advertisement which had to reduce its workforce by 30% due to “the changing market conditions and a modified business plan”. Northvolt wants to reduce everything possible and focus on its Swedish plant, but they have also signed an agreement with Volvo to explore joint collaboration paths in the future, so everything is not lost. China looks out to Europe. Therefore, Volvo will now be the one Novo Energy, we will see if alone or with partners, but the interesting thing about this operation is that, although Volvo is a Swedish company that is in the bag of his country, the matrix is ​​Geely, A Chinese holding. They are present in multitude of companies and sectors, with an important participation in Mercedes-Benz, Aston Martin or Lotus, as well as co-owners of smart, polestar and with a participation of more than 80% in Volvo. It is curious that Northvolt was born to stand up to the Chinese battery industry and that the Join Adventure That I had with Volvo to produce batteries in Europe, now, is controlled by a Chinese company, in the absence of seeing the resolution of the authorities. And all this, shortly after Tariffs imposed by Europe To the Chinese electric car. In Xataka | Catl’s investment in Spain is not accidental: China is punishing those who supported tariffs on their electric cars

Log In

Forgot password?

Forgot password?

Enter your account data and we will send you a link to reset your password.

Your password reset link appears to be invalid or expired.

Log in

Privacy Policy

Add to Collection

No Collections

Here you'll find all collections you've created before.